Downside to 10c is very, very unlikely.
BNC 210 has already shown good Phase II results for General Anxiety Disorder and it appears that there is at least some positive indications for Agitation, so a complete write off of BNC 210 is a ridiculous suggestion - sorry.
If the results are good the $1.00 will not stop the share price in my view.
It is not beyond the realms of possibility that Merck has indicted to the company that they will license the drug if it meets certain targets in this trial.
If Deborah is in the US this weekend, then it would not surprise.
However, this is pure speculation.
As frustrated as I have been with the company ove rthe years, all we can do now id not fret but just wait and see.
Given that Sydney and Adelaide are on holiday on Monday, I would expect an announcement erly Tuesday.
GLTA.
On to the moon or curtains, page-2
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
